Title of article
Effects of Concomitant use of silymarin on solid tumors chemotherapy: a pilot randomized controlled trial
Author/Authors
Sadighi ، Sanambar - Tehran University of Medical Sciences , Dashti-Khavidaki ، Simin - Tehran University of Medical Sciences , Shahbazi ، Foroud - Kermanshah University of Medical Sciences , Mirzania ، Mehrzad - Tehran University of Medical Sciences , Shahi ، Farhad - Tehran University of Medical Sciences , Abdollahi ، Alireza - Tehran University of Medical Sciences , Ghahremani ، Mohammad Hossein - Tehran University of Medical Sciences
Pages
5
From page
13
To page
17
Abstract
Anticancer potential of silymarin have been shown in cell culture. However, regarding this matter no prospective clinical study has been done. In a randomized double blind pilot study, we compared effects of addition of standard chemotherapy along with silymarin (420mg/day) versus placebo on clinical response of advanced tumors after three cycles of cisplatinbased chemotherapy. There was no significant difference in tumor size after three consecutive chemotherapy courses but a trend toward lower metastasis rate in chemotherapy + silymarin group. Concomitant use of silymarin along with chemotherapy was very well tolerated but didn’t significantly increase clinical response. Due to trend toward significant lower metastasis in silymarin group, further study with larger sample size is needed to better clarify probable role of adjunctive therapy with silymarin in patients with solid tumors.
Keywords
silymarin , anticancer , solid tumor , chemotherapy
Journal title
Basic and Clinical Cancer Research
Serial Year
2017
Journal title
Basic and Clinical Cancer Research
Record number
2454074
Link To Document